Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000709840 | SCV001092538 | likely benign | STT3B-congenital disorder of glycosylation | 2024-04-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004026785 | SCV003739012 | uncertain significance | not specified | 2022-06-30 | criteria provided, single submitter | clinical testing | The c.895A>G (p.I299V) alteration is located in exon 6 (coding exon 6) of the STT3B gene. This alteration results from a A to G substitution at nucleotide position 895, causing the isoleucine (I) at amino acid position 299 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Breakthrough Genomics, |
RCV004711295 | SCV005258395 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Genome |
RCV000709840 | SCV000840170 | not provided | STT3B-congenital disorder of glycosylation | no assertion provided | phenotyping only | GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. |